Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNYSE:BHVNNASDAQ:DYNNASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.82+1.1%$13.88$7.86▼$17.75$1.63B1.762.25 million shs1.90 million shsBHVNBiohaven$14.51+0.8%$17.90$13.87▼$55.70$1.47B0.951.28 million shs2.79 million shsDYNDyne Therapeutics$10.32-4.3%$11.60$6.36▼$47.45$1.23B1.161.76 million shs4.04 million shsPGENPrecigen$1.45-2.7%$1.43$0.65▼$2.17$439.82M1.841.37 million shs2.11 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+1.10%+2.90%+0.44%-18.75%+69.57%BHVNBiohaven+0.88%-5.97%-7.82%-49.30%-55.74%DYNDyne Therapeutics-4.27%-28.38%-12.24%-14.57%-68.87%PGENPrecigen-2.68%-4.61%+9.85%-19.89%-7.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.284 of 5 stars3.41.00.00.03.31.70.6BHVNBiohaven2.998 of 5 stars4.51.00.00.01.62.50.6DYNDyne Therapeutics2.3786 of 5 stars4.50.00.00.01.82.50.0PGENPrecigen3.9743 of 5 stars3.51.00.04.72.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8036.03% UpsideBHVNBiohaven 3.07Buy$58.46303.04% UpsideDYNDyne Therapeutics 3.00Buy$43.93325.66% UpsidePGENPrecigen 3.00Buy$6.00313.79% UpsideCurrent Analyst Ratings BreakdownLatest PGEN, BHVN, ARQT, and DYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.006/18/2025DYNDyne TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/18/2025DYNDyne TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.006/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/11/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/19/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M8.38N/AN/A$1.35 per share10.24BHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/ADYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/APGENPrecigen$4.20M101.88N/AN/A$0.13 per share11.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)BHVNBiohaven-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)Latest PGEN, BHVN, ARQT, and DYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.753.553.37BHVNBiohavenN/A2.332.33DYNDyne TherapeuticsN/A20.3520.35PGENPrecigenN/A3.533.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABHVNBiohaven88.78%DYNDyne Therapeutics96.68%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BHVNBiohaven16.00%DYNDyne Therapeutics14.14%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableBHVNBiohaven239102.11 million85.78 millionOptionableDYNDyne Therapeutics100113.67 million97.59 millionOptionablePGENPrecigen190295.18 million156.15 millionOptionablePGEN, BHVN, ARQT, and DYN HeadlinesRecent News About These CompaniesJMP Securities Reaffirms Market Outperform Rating for Precigen (NASDAQ:PGEN)June 14, 2025 | americanbankingnews.comCantor Fitzgerald Weighs in on Precigen FY2026 EarningsJune 13, 2025 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Earns Market Outperform Rating from JMP SecuritiesJune 12, 2025 | marketbeat.comPrecigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutionsJune 12, 2025 | finance.yahoo.comCantor Fitzgerald Estimates Precigen FY2026 EarningsJune 11, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 792,731 Shares of Precigen, Inc. (NASDAQ:PGEN)May 27, 2025 | marketbeat.comPrecigen (NASDAQ:PGEN) Downgraded to "Sell" Rating by Wall Street ZenMay 26, 2025 | marketbeat.comFY2025 EPS Estimates for Precigen Cut by Cantor FitzgeraldMay 21, 2025 | marketbeat.comHC Wainwright Decreases Earnings Estimates for PrecigenMay 21, 2025 | marketbeat.comJ.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)May 20, 2025 | theglobeandmail.comPrecigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business UpdatesMay 18, 2025 | finanznachrichten.deCantor Fitzgerald maintains Overweight on Precigen stockMay 17, 2025 | uk.investing.comPrecigen Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | prnewswire.comPrecigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11thApril 16, 2025 | prnewswire.comIs Precigen (PGEN) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comPrecigen options imply 20.1% move in share price post-earningsMarch 20, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)March 20, 2025 | markets.businessinsider.com4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 AnalystsMarch 20, 2025 | benzinga.comPrecigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business UpdatesMarch 20, 2025 | finanznachrichten.dePrecigen Reports Progress and Financial Results for 2024March 19, 2025 | tipranks.comPrecigen, Inc. (PGEN) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePGEN, BHVN, ARQT, and DYN Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.82 +0.15 (+1.10%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.88 +0.06 (+0.43%) As of 06/20/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Biohaven NYSE:BHVN$14.50 +0.12 (+0.80%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$14.48 -0.03 (-0.21%) As of 06/20/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Dyne Therapeutics NASDAQ:DYN$10.32 -0.46 (-4.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$10.52 +0.21 (+1.99%) As of 06/20/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Precigen NASDAQ:PGEN$1.45 -0.04 (-2.68%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06/20/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
